12.3 Enhanced Elimination: Urinary Alkalinization, MDAC, Hemodialysis, and Hemoperfusion

When a toxic dose of a xenobiotic has already been absorbed into the systemic circulation and cannot be neutralized by a specific antidote, clinical management shifts toward enhanced elimination. These advanced therapeutic modalities accelerate the rate of drug removal from blood and tissues, shortening the duration of severe toxicity and preventing irreversible end-organ damage. The three primary clinical strategies for enhanced elimination are urinary alkalinization (ion trapping), multiple-dose activated charcoal (gastrointestinal dialysis), and extracorporeal techniques (hemodialysis and hemoperfusion).

---

Urinary Alkalinization and Ion Trapping

Urinary alkalinization is a non-invasive enhanced elimination technique that manipulates renal tubular fluid pH to accelerate the renal clearance of weak acid xenobiotics.

1. Biophysical Chemistry: The Henderson-Hasselbalch Equilibrium

Weak acids exist in equilibrium between an uncharged, non-ionized, lipid-soluble form (HA) and a charged, ionized, water-soluble conjugate base (A⁻):

$\text{pH} = \text{p}K_a + \log\left(\frac{[A^-]}{[HA]}\right)$

Renal Tubular Mechanism of Ion Trapping:
Glomerular Filtrate (Urine pH 7.5 to 8.0)    │    Renal Tubular Epithelium    │    Peritubular Capillary Blood
────────────────────────────────────────────┼────────────────────────────────┼──────────────────────────────
Weak Acid Toxin Enters Lumen (HA ⇌ A⁻ + H⁺) │                                │
                                            │                                │
Alkaline Tubular Fluid Deprotonates Acid    │                                │
  HA + HCO3⁻ ──► A⁻ + H2CO3                 │                                │
                                            │  LIPID BILAYER BARRIER         │
Charged Anion (A⁻) Cannot Cross Membrane    │  (Charged molecules excluded)  │
                                            │                                │
TRAPPED IN URINARY LUMEN ──► EXCRETED       │  Non-ionized (HA) diffusible   │

• In normal acidic urine (pH 5.0 to 6.5), weak acid xenobiotics with a pKa between 3.0 and 7.5 (such as salicylic acid, pKa approximately 3.0 to 3.5, or phenobarbital, pKa approximately 7.2) exist predominantly in their non-ionized (HA) form. Because non-ionized molecules are lipid-soluble, they passively diffuse out of the tubular lumen across the renal tubular epithelial cell membranes and back into the peritubular capillaries (passive tubular reabsorption).
• When the urine is alkalinized to a pH of 7.5 to 8.0, the equilibrium shifts dramatically to the right. The weak acid deprotonates into its charged conjugate base (A⁻). Lipid bilayers are virtually impermeable to charged ionic species; therefore, the ionized toxin is physically 'trapped' within the tubular lumen and eliminated in the urine. For salicylates, raising urine pH from about 5 to 8 increases renal salicylate clearance roughly 10- to 20-fold.

2. Clinical Indications for Urinary Alkalinization

• Salicylates (Aspirin, Methyl Salicylate): Primary clinical indication. Accelerates renal excretion while systemic alkalinization prevents salicylate entry into brain tissue.
• Phenobarbital: Weak acid barbiturate (pKa 7.2). Significantly accelerated clearance, though less frequently required today due to hemodialysis and MDAC.
• Chlorpropamide: Long-acting sulfonylurea (pKa 5.0).
• Methotrexate: High-dose chemotherapy toxicity; alkalinization prevents intraluminal precipitation of methotrexate and 7-hydroxymethotrexate in the collecting ducts.
• Chlorophenoxy Herbicides (2,4-D and Mecoprop): Marked acceleration of renal elimination.

3. Clinical Administration Protocol and Target Goals

• Solution Preparation: Add 100 to 150 mEq of sodium bicarbonate (typically two to three 50 mL ampules of 8.4% NaHCO₃) to 1 liter of 5% dextrose in water (D5W). Co-infuse 20 to 40 mEq of potassium chloride (KCl).
• Infusion Rate: Administer at 1.5 to 2 times maintenance intravenous fluid rates (approximately 150 to 250 mL/hr in adults), or initiate with an initial IV bolus of 1 to 2 mEq/kg followed by continuous infusion.
• Target Urinary pH: Maintain urine pH strictly between 7.5 and 8.0 (checked at every void or hourly via indwelling Foley catheter).
• Target Serum / Arterial pH: Maintain systemic blood pH between 7.45 and 7.55.
• Critical Safety Ceiling: Arterial blood pH must never exceed 7.55 to 7.60. Severe systemic alkalemia induces cerebral vasoconstriction, reduces ionized serum calcium (triggering tetany and seizures), and provokes malignant ventricular dysrhythmias.

4. The Critical Role of Potassium: Preventing Paradoxical Aciduria

The Hypokalemia - Paradoxical Aciduria Cascade:
Bicarbonate Infusion Drives Systemic Alkalemia ──► Shifts K+ into Intracellular Compartment
                                                          │
                                                          ▼
                                              Severe Serum Hypokalemia (< 4.0 mEq/L)
                                                          │
                                                          ▼
                             Renal Cortical Collecting Tubule Intercalated Cells Stressed
                                                          │
                                                          ▼
                             H+/K+-ATPase Pump Activated to Conserve Potassium
                                                          │
                                                          ▼
                             Pumps H+ Ions Directly INTO Urinary Lumen While Reabsorbing K+
                                                          │
                                                          ▼
                             PARADOXICAL ACIDURIA (Urine pH Drops to 5.5 - 6.0 Despite High Serum pH)
                                                          │
                                                          ▼
                             ION TRAPPING FAILS ──► Salicylate Systemic Toxicity Accelerates

In the distal convoluted tubule and cortical collecting ducts, type A intercalated cells utilize an active H⁺/K⁺-ATPase exchanger to regulate acid-base and potassium balance. When a patient develops hypokalemia:

1. The kidneys prioritize systemic potassium conservation over systemic acid-base balance.
2. The H⁺/K⁺-ATPase pump activates, actively reabsorbing potassium ions from the tubular fluid while pumping hydrogen ions (H⁺) into the tubular lumen.
3. This results in paradoxical aciduria—the urine remains stubbornly acidic (pH 5.5 to 6.5) despite severe systemic alkalemia (blood pH 7.50).
4. Clinical Directive: The CSPI must aggressively monitor and replete potassium, targeting a serum potassium of 4.0 to 4.5 mEq/L. If the urine fails to alkalinize despite massive bicarbonate infusions, the cause is almost invariably uncorrected hypokalemia.

---

Multiple-Dose Activated Charcoal (MDAC)

Multiple-Dose Activated Charcoal (MDAC)—also known as 'gastrointestinal dialysis'—involves the repeated administration of oral activated charcoal over an extended period to accelerate the systemic elimination of xenobiotics that have already been completely absorbed into the bloodstream.

Mechanism of Gastrointestinal Dialysis:
Systemic Circulation (High Free Drug Concentration in Mesenteric Capillary Bed)
                                  │
                                  ▼
               Intestinal Mucosal Capillary Semi-Permeable Barrier
                                  │
                                  ▼
Gut Lumen (Charcoal Binds Dissolved Drug, Maintaining Near-Zero Free Drug Concentration)
                                  │
                                  ▼
Continuous Passive Trans-Mucosal Diffusion of Free Drug from Capillaries into Gut Lumen
                                  │
                                  ▼
Irreversible Adsorption to Charcoal + Excretion in Stool (Systemic Clearance Accelerated)

1. Dual Mechanisms of Clearance

MDAC accelerates systemic clearance through two independent physiological mechanisms:

1. Gastrointestinal Dialysis: The gut lumen acts as a dialyzer membrane. Charcoal in the gastrointestinal tract adsorbs any dissolved free xenobiotic, driving luminal free drug concentration to near zero. This establishes a steep concentration gradient between mesenteric capillary blood and the gut lumen, drawing drug out of the blood across the intestinal mucosa into the gut, where it is irreversibly bound and excreted.
2. Interruption of Enterohepatic and Enteroenteric Recirculation: Many xenobiotics undergo biliary excretion as parent drug or glucuronide conjugates. In the small intestine, bacterial beta-glucuronidases hydrolyze conjugates, freeing the lipophilic parent drug for reabsorption back into portal circulation. MDAC intercepts biliary secretions, binding the drug before reabsorption occurs.

2. Indications: The AACT/EAPCCT "Big Five"

The joint AACT/EAPCCT position statement advises considering MDAC only after a life-threatening ingestion of one of five drugs with evidence of enhanced elimination. A simple memory aid is "Can Do Phenomenal Quality Therapy":

MDAC Indications (AACT/EAPCCT):
C - Carbamazepine
D - Dapsone
P - Phenobarbital
Q - Quinine
T - Theophylline (including aminophylline)

Enhanced elimination has also been reported for other agents (for example, digitoxin and some plant cardiac glycosides), but outcome benefit is not established.

3. Dosing Protocol and Administration Guidelines

• Initial Loading Dose: 1 g/kg (or 50 to 100 g in adults) orally or via nasogastric tube (may be administered with a single dose of sorbitol cathartic).
• Subsequent Maintenance Doses: 0.25 to 0.5 g/kg (or 25 to 50 g in adults) administered every 2 to 4 hours, or given as a continuous NG infusion of 12.5 to 25 g/hr.
• THE ABSOLUTE CATHARTIC RULE: Cathartics (sorbitol, magnesium citrate) must NEVER be repeated with multiple doses of charcoal. A cathartic may only accompany the very first dose. Repeated cathartics cause devastating osmotic diarrhea, hypovolemia, hypernatremia, and hypokalemia.

4. Contraindications and Clinical Monitoring

• Absent Bowel Sounds or Abdominal Distension: Auscultate the abdomen before every single dose. If bowel sounds become absent, or if nausea, vomiting, or distension develop, hold MDAC immediately. Ingested xenobiotics with anticholinergic or sedative properties (e.g., carbamazepine) induce ileus. Continuing charcoal against an ileus causes charcoal concretions, intestinal impaction, bowel obstruction, and intestinal perforation.
• Unprotected Airway: Obtunded patients must be intubated prior to MDAC administration to prevent fatal aspiration pneumonitis.

---

Extracorporeal Elimination: Hemodialysis and Hemoperfusion

Extracorporeal elimination involves diverting blood through an external circuit containing a semipermeable membrane (hemodialysis) or an adsorbent cartridge (hemoperfusion) to directly clear xenobiotics from the intravascular compartment.

1. Physicochemical Determinants of Dialyzability

Not all poisoned patients can be treated with hemodialysis. To be successfully eliminated via intermittent hemodialysis, a xenobiotic must possess specific molecular and pharmacokinetic properties:

Ideal Xenobiotic Profile for Hemodialysis Removal:
[Molecular Weight < 500 Da]  +  [Protein Binding < 70-80%]  +  [Volume of Distribution < 1.0 L/kg]  +  [High Water Solubility]

1. Low Molecular Weight (< 500 Daltons): Small molecules easily cross the pores of standard cellulose or synthetic dialyzer membranes. Molecules larger than 1,000 to 1,500 Da are poorly cleared by conventional hemodialysis.
2. Low Plasma Protein Binding (< 70% to 80%): Only the free, unbound fraction of drug dissolved in plasma water is small enough to diffuse across the dialyzer membrane. Highly protein-bound drugs (e.g., phenytoin, > 90% bound; diazepam, > 98% bound) cannot cross the membrane.
3. Small Volume of Distribution (Vd < 1.0 L/kg): Xenobiotics with a small Vd reside primarily within the intravascular space, making them readily accessible to the dialyzer circuit. Drugs with a large Vd (> 2.0 to 5.0 L/kg, such as digoxin, TCAs, chloroquine) are sequestered deeply within adipose and peripheral tissues; plasma contains less than 1% to 2% of the total body burden, rendering hemodialysis futile.
4. High Water Solubility: Facilitates rapid diffusion out of blood into aqueous dialysate fluid.

2. EXTRIP Workgroup Recommendations

The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup, an international panel of toxicologists, nephrologists, and pharmacists, publishes graded recommendations ("recommended" vs. "suggested"). Intermittent hemodialysis is the preferred modality for every agent below.

Rebound matters. Lithium redistributes out of cells after dialysis, so EXTRIP advises serial lithium levels over the following 12 hours to decide on repeat sessions. Continue antidotes during ECTR (fomepizole and folate for toxic alcohols, NAC at an increased rate for acetaminophen, bicarbonate between salicylate sessions).

3. Charcoal Hemoperfusion

In charcoal hemoperfusion, anticoagulated whole blood is pumped directly through an extracorporeal cartridge containing polymer-coated activated charcoal or resin granules.

• Mechanistic Advantage: The blood is in direct contact with charcoal, allowing the cartridge to adsorb lipophilic and moderately protein-bound xenobiotics that cannot cross hemodialysis membranes.
• Historic Indications: Severe theophylline, carbamazepine, and paraquat poisonings.
• Major Complications: Severe thrombocytopenia (platelets adhere to charcoal granules), hypocalcemia, leukopenia, and circuit clotting.
• Current Role: Charcoal cartridges are expensive, rarely stocked by hospitals, and carry high complication rates. Modern high-flux, high-efficiency hemodialysis achieves clearance rates approaching hemoperfusion, making intermittent hemodialysis the modality of choice.

4. Continuous Renal Replacement Therapy (CRRT)

Continuous venovenous hemofiltration (CVVH) and hemodiafiltration (CVVHDF) are designed for slow, continuous solute and volume removal in hemodynamically unstable intensive care patients.

• Clearance Comparison: CRRT clearance rates (20 to 40 mL/min) represent only 15% to 25% of the clearance achieved by intermittent hemodialysis (200 to 300 mL/min).
• Toxicological Role: CRRT is inferior to intermittent hemodialysis for acute toxic clearance and should never be used as the initial primary therapy for life-threatening poisoning (such as severe methanol or salicylate overdose). It is properly reserved as a maintenance therapy following intermittent hemodialysis to prevent rebound redistribution (e.g., in lithium toxicity) or when intermittent hemodialysis is unavailable.